NO20090064L - Pyrasoler som glucokinase aktivatorer - Google Patents

Pyrasoler som glucokinase aktivatorer

Info

Publication number
NO20090064L
NO20090064L NO20090064A NO20090064A NO20090064L NO 20090064 L NO20090064 L NO 20090064L NO 20090064 A NO20090064 A NO 20090064A NO 20090064 A NO20090064 A NO 20090064A NO 20090064 L NO20090064 L NO 20090064L
Authority
NO
Norway
Prior art keywords
pyrasols
glucokinase activators
glucokinase
activators
disorders
Prior art date
Application number
NO20090064A
Other languages
English (en)
Inventor
Robert Francis Kester
Ramakanth Sarabu
Steven Joseph Berthel
Douglas Eric Murphy
Thomas Jay Prins
Frank Ruebsam
Chinh Viet Tran
Dionisios Vourloumis
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20090064L publication Critical patent/NO20090064L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Her er beskrevet pyrazol glucokinase aktivatorer med formel (I) (I) hvor R1 til R4 er som definert i beskrivelsen og kravene anvendelige for behandling av metabolske sykdommer og lidelser, fortrinnsvis diabetes mellitus.
NO20090064A 2006-07-24 2009-01-06 Pyrasoler som glucokinase aktivatorer NO20090064L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83290706P 2006-07-24 2006-07-24
US93081907P 2007-05-18 2007-05-18
PCT/EP2007/057315 WO2008012227A2 (en) 2006-07-24 2007-07-16 Pyrazoles as glucokinase activators

Publications (1)

Publication Number Publication Date
NO20090064L true NO20090064L (no) 2009-02-04

Family

ID=38657003

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090064A NO20090064L (no) 2006-07-24 2009-01-06 Pyrasoler som glucokinase aktivatorer

Country Status (16)

Country Link
US (1) US7935699B2 (no)
EP (2) EP2046755A2 (no)
JP (1) JP2009544648A (no)
KR (1) KR20090025358A (no)
AR (1) AR062012A1 (no)
AU (1) AU2007278261A1 (no)
BR (1) BRPI0715531A2 (no)
CA (1) CA2657566A1 (no)
CL (1) CL2007002121A1 (no)
IL (1) IL196321A0 (no)
MX (1) MX2009000688A (no)
NO (1) NO20090064L (no)
PE (1) PE20080406A1 (no)
RU (1) RU2009105818A (no)
TW (1) TWI332948B (no)
WO (1) WO2008012227A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
US8034819B2 (en) 2007-03-07 2011-10-11 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
AU2009205070A1 (en) * 2008-01-18 2009-07-23 Astellas Pharma Inc. Phenyl acetamide derivative
US7741327B2 (en) * 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
CN102089291B (zh) 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物
UA104742C2 (uk) * 2008-12-19 2014-03-11 Эли Лилли Энд Компани Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
JP5680052B2 (ja) * 2010-02-23 2015-03-04 セーレン株式会社 透湿防水布帛
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
EP2402327B1 (en) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Acetamide compounds as glucokinase activators, their process and medicinal applications
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
PT2655375E (pt) 2010-12-23 2015-03-02 Sanofi Sa Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
US8470866B2 (en) 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
AU2013321961A1 (en) * 2012-09-26 2015-03-05 Kowa Company, Ltd. Novel phenylacetamide compound and pharmaceutical containing same
TN2016000542A1 (en) 2014-06-03 2018-04-04 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
ES2693052T3 (es) 2014-09-15 2018-12-07 Idorsia Pharmaceuticals Ltd Compuestos de triazol como bloqueantes de los canales de calcio de tipo T
HRP20220463T1 (hr) 2016-12-16 2022-05-27 Idorsia Pharmaceuticals Ltd Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa
WO2018141961A1 (en) 2017-02-06 2018-08-09 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
CN108947940A (zh) * 2018-06-20 2018-12-07 天津全和诚科技有限责任公司 一种2-氧杂环丁烷衍生物的合成方法
CN108727309B (zh) * 2018-06-20 2023-04-07 天津全和诚科技有限责任公司 一种3-氧杂环丁烷羧酸的合成方法
CN109053496B (zh) * 2018-08-09 2020-10-20 吉尔生化（上海）有限公司 一种3-Boc-氨甲基环丁酮的合成方法
CN114940658A (zh) * 2022-05-12 2022-08-26 山东华阳药业有限公司 一种色瑞替尼的制备工艺及其制备方法
CN120136817A (zh) * 2025-05-16 2025-06-13 安徽泽升科技股份有限公司 一种氧杂环丁烷-3-甲醇和氧杂环丁烷-3-甲醛的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1046139B (zh) 1999-03-29 2004-12-10 霍夫曼-拉罗奇有限公司 葡糖激酶活化剂
EP1282612B1 (en) 2000-05-03 2004-12-29 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
BR0110704A (pt) 2000-05-08 2003-01-28 Hoffmann La Roche Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
MXPA02010795A (es) 2000-05-08 2003-03-27 Hoffmann La Roche Activadores de glucocinasa de fenilamida sustituida por para-amino.
EP1341774B1 (en) 2000-12-06 2006-02-01 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
BR0309546A (pt) 2002-04-26 2005-02-15 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
JP4621198B2 (ja) 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
WO2004076420A1 (ja) * 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
EP2048137A1 (en) 2004-02-18 2009-04-15 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents.
JP2007523905A (ja) 2004-02-18 2007-08-23 アストラゼネカ アクチボラグ 化合物
AU2005223610B2 (en) 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
US7781451B2 (en) 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
PT1735322E (pt) 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
EA012204B1 (ru) 2004-04-21 2009-08-28 Прозидион Лимитед Три(цикло)замещённые амидные соединения
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0418046D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
MX2007001650A (es) * 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
AU2005311269B2 (en) 2004-12-03 2011-11-10 Transtech Pharma, Inc. Heteroaromatic glucokinase activators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP2027113A1 (en) 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
US20110053910A1 (en) 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
RU2420525C2 (ru) 2005-07-11 2011-06-10 Мицубиси Танабе Фарма Корпорейшн Производные оксимов и их получение
WO2007017649A1 (en) 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
AU2006285834A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
CA2626475A1 (en) * 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
JP2009514836A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
EP2010520B1 (en) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases

Also Published As

Publication number Publication date
WO2008012227A3 (en) 2008-05-15
WO2008012227A2 (en) 2008-01-31
AR062012A1 (es) 2008-08-10
KR20090025358A (ko) 2009-03-10
AU2007278261A1 (en) 2008-01-31
CL2007002121A1 (es) 2008-02-22
TW200812974A (en) 2008-03-16
TWI332948B (en) 2010-11-11
MX2009000688A (es) 2009-01-30
BRPI0715531A2 (pt) 2014-06-24
EP2261216A3 (en) 2011-12-14
US20080021032A1 (en) 2008-01-24
EP2046755A2 (en) 2009-04-15
US7935699B2 (en) 2011-05-03
JP2009544648A (ja) 2009-12-17
EP2261216A2 (en) 2010-12-15
CA2657566A1 (en) 2008-01-31
IL196321A0 (en) 2009-09-22
WO2008012227A8 (en) 2008-09-12
RU2009105818A (ru) 2010-08-27
PE20080406A1 (es) 2008-04-28

Similar Documents

Publication Publication Date Title
WO2008012227A8 (en) Pyrazoles as glucokinase activators
UA97817C2 (ru) Гетероциклические производные 4-(метилсульфонил)фенила и их применение
ATE539748T1 (de) Glucokinaseaktivatoren
MX2010009922A (es) Activadores de piridazinona glucocinasa.
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
NO20074872L (no) Pyrazoler
NO20075626L (no) Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes
ECSP055916A (es) Derivados de arilo y heteroarilo 1, 2, 3, trisubstituidos como moduladores de metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia
CY1108736T1 (el) Φαινυλ-και πυριδυλπιπεριδινο-παραγωγα ως ρυθμιστες μεταβολισμου γλυκοζης
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
WO2008055870A8 (en) Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008034859A8 (en) Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
NO20076658L (no) Heteroarylbenzamidderivater for anvendelse som GLK aktivatorer ved behandling av diabetes
NO20065868L (no) Substituerte aryl- og heteroarylderivater som metabolisme- og profylkasemodulatorer og behandling av forstyrrelser forbundet med dette
NO20073806L (no) Substituerte pyridinyl og pyrimidinylderivater som modulatorer av metabolisme og behandling av lidelser relatert til dette
NO20085067L (no) 4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
MY157911A (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
EA201000515A1 (ru) Активаторы глюкокиназы
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20065260L (no) Tri(cyklo)substituerte amidforbindelser
DE502006006107D1 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application